Sign up
Pharma Capital

Q BioMed Inc awaits FDA approval of facility to manufacture 'revenue ready' pain drug

Q BioMed Inc (OTC US:QBIO:) CEO Denis Corin tells Proactive Investors the commercial-stage biotechnology acceleration company is waiting for the US Food and Drug Administration to sign off on a new manufacturing facility to produce Strontium Chloride Sr89 injection.

Corin says he is hopeful the FDA will approve the facility in the next 30 days and is excited to bring the non-opioid pain analgesic to the market.

 

View full QBIO profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.